Skip to main content
SpringerLink
Log in

Salmeterol: An inhaled /β2-agonist with prolonged duration of action

  • Review
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Salmeterol (Serevent) is an inhaled beta2-receptor agonist with more than twelve hours’ effect duration compared with 4–6 hours for the more short-acting substances bitolterol, fenoterol, salbutamol, and terbutaline. Salmeterol has been studied in several large-scale double-blind multicenter studies with up to one year’s duration. More than 6,000 asthmatics have been treated with salmeterol during these controlled studies. All studies show salmeterol to have a significantly better and well-maintained bronchodilating effect with better asthma control, fewer asthma exacerbations, and a decreased need for rescue albuterol inhalations used on demand compared to the treatments in the control groups (200–400 μg albuterol q.i.d., inhaled albuterol given only p.r.n., terbutaline given regularly, or individually titrated slow-release theophylline). Salmeterol should be given b.i.d. and in combination with inhaled corticosteroids. Salmeterol seems especially effective in patients with nocturnal symptoms, exercise induced asthma, and in patients sensitive to inhaled irritants such as cold air. The patients should always have short-acting inhaled beta2-agonists available for break-through attacks. Inhaled salmeterol in combination with inhaled steroids seems to give the best maintenance asthma control available by inhalation today.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson SD, Rodwell LT, Du Toit J, Young IH (1991) Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 100:1254–60

    Article  Google Scholar 

  2. Arvidsson P, Larsson S, Löfdahl CG, Melander B, Wahlander L, Svedmyr N (1989) Formoterol, a new long acting bronchodilator for inhalation. Eur Respir J 2:325–330

    PubMed  CAS  Google Scholar 

  3. 3. British Thoracic Society (1993) Guidelines for the management of asthma. Br Med J 300:776–782

    Google Scholar 

  4. Britton MG, Earnshaw JS, Palmer JBD (1992) A twelve-month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 5:1062–1067

    PubMed  CAS  Google Scholar 

  5. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ (1992) Long-term effects of a long-acting β2-adrenoceptor agonist, salmeterol on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327:1198–1203

    Article  PubMed  CAS  Google Scholar 

  6. Crane J, Flatt A, Jackson R, Ball M, Pearce N, Burgess C, Kwong T, Beasley R (1989) Prescribed fenoterol and death from asthma in New Zealand. Lancet 1, 917–922

    Article  PubMed  CAS  Google Scholar 

  7. Dahl R, Pedersen B, Venge P (1991) Bronchoalveolar lavage studies. Eur Respir Rev 1:272–275

    Google Scholar 

  8. Dearom EY, Pauwels RA, Van Der Straeten MEF (1992) The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol 89:811–815

    Article  Google Scholar 

  9. Douglas NJ, Fitzpatrick MF (1991) Effects of salmeterol on nocturnal asthma. Eur Respir Rev 1:293–296

    Google Scholar 

  10. Faurschou P (1991) Chronic dose-ranging studies with salmeterol. Eur Respir Rev 1:282–287

    Google Scholar 

  11. Fjellbirkeland L, Gulsvik A (1990) Salmeterol and theophylline sustained release: a crossover comparison in asthmatic patients (abstract). Clin Exper Allergy 20 (suppl 1):OP115

    Google Scholar 

  12. Grainger J, Woodman K, Pearce N, Crane J, Burgress C, Keane A, Beaslye R (1991) Prescribed fenoterol and death from asthma in New Zealand 1981–1987: a further case control study. Thorax 46:105–111

    Article  PubMed  CAS  Google Scholar 

  13. Haahtela T, Järvinen M, Kava T, et al. (1991) Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 325:388–392

    Article  PubMed  CAS  Google Scholar 

  14. Harvey JE, Tattersfield AE (1982) Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 37:280–287

    Article  PubMed  CAS  Google Scholar 

  15. Howarth PH (1992) Optimising asthma therapy: bronchial biopsies. In: Clark TJH, Fabbri LM (eds) Satellite Symposium of the First Annual Congress of the European Respiratory Society. Excerpta Medica, 14–19

  16. Jeffery PK, Godfrey RW, Ädelroth E et al. (1992) Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 145:890–899

    PubMed  CAS  Google Scholar 

  17. Jenne JW, Conolly ME, Hui KK, Borst SE (1987) Beta-adrenergic tachyphylaxis (desensitization) and functional antagonist in drug therapy for asthma. In: Jenne JW, Murphy S (ed) Lung biology in health and disease. Marcel Dekker, New York, 31:259–296

    Google Scholar 

  18. Johnson M (1992) Long-acting /32-adrenoceptor agonists. In: PJ Barnes (ed) New drugs for asthma, vol 2. IBC Technical Services, Oxford, U.K., pp 18–32

    Google Scholar 

  19. Juniper EF, Kline PA, Vanzieleghem MA, et al. (1990) Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 142:832–836

    PubMed  CAS  Google Scholar 

  20. Kay B (1989) The role of inflammatory processes in airway hyperresponsiveness: cellular mechanisms. In: Holgate ST (ed) Blackwell Scientific Publications, Oxford, UK, 151–178

    Google Scholar 

  21. Lipworth BJ (1992) Risks versus benefits of inhaled β2-agonists in the management of asthma. Drug Safety 7:54–70

    Article  PubMed  CAS  Google Scholar 

  22. Löfdahl CG (1982) Selectivity of β2-adrenoceptor agonists and antagonists in asthmatics. Eur J Respir Dis 63:suppl 120:1–53

    Google Scholar 

  23. Löfdahl C-G, Chung KF (1991) Long-acting β2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J 1:218–226

    Google Scholar 

  24. Lötvall J, Lunde H, Ullman A, Svedmyr N (1992) Twelve months’ treatment with inhaled salmeterol in asthmatic patients: effects on β2-receptor function and inflammatory cells. Allergy 47:477–483

    Article  PubMed  Google Scholar 

  25. Lundbäck B, Rawlinson DW, Palmer JBD (1993) Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 48:148–153

    Article  PubMed  Google Scholar 

  26. Malo JL, Ghezzo H, Trudeau Cl, L’Archevêque J, Cartier A. Salmeterol (1992) A new inhaled beta2-agonist has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol 89:567–574

    Article  PubMed  CAS  Google Scholar 

  27. Medical Products Agency (1993) Pharmacological treatment of bronchial asthma II. Medical Products Agency, Uppsala, Sweden 1:1–186

    Google Scholar 

  28. Muir JF, Bertin L, Georges D (1992) Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicenter trial. Eur Respir J 5:1197–1200

    PubMed  CAS  Google Scholar 

  29. 29. National Heart, Lung, and Blood Institute, USA (1992) The International Asthma Project. International consensus report on diagnosis and management of asthma (NIH). Allergy 47, suppl

  30. Nowak D, Jörres R, Rabe KF, Lüthke M, Wiessmann J, Magnussen H (1992) Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. Eur J Clin Pharmacol 43:591–595

    Article  PubMed  CAS  Google Scholar 

  31. O’Connor B, Aikman SL, Barnes PJ (1992) Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma. N Engl J Med 327:1204–1208

    Article  PubMed  Google Scholar 

  32. Palmer J, Hyland ME (1991) Salmeterol in clinical practice: comparator and safety studies, quality of life studies. Eur Respir Rev 1:301–303

    Google Scholar 

  33. Palmer JBD, Stuart AM, Shepherd GL, Viskum K (1992) Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease—a 3-months comparison of the efficacy and safety of twice-daily salmeterol (100 μg) with salmeterol (50 μg). Respir Med 86:409–417

    Article  PubMed  CAS  Google Scholar 

  34. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, Windon H, Beasley R (1990) Case control study of prescribed fenoterol and death from asthma 1977–1981. Thorax 45:170–175

    Article  PubMed  CAS  Google Scholar 

  35. Pearlman DS, Chervinsky P, LaForce C, et al. (1992) A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 327:1420–1425

    Article  PubMed  CAS  Google Scholar 

  36. Peel ET, Gibson GJ (1980) Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine. Am Rev Respir Dis 121:973–978

    PubMed  CAS  Google Scholar 

  37. Sears MR, Taylor DR, Print CG, Lake DC, Qingqing L, Flannery EM, Yates DM, Lucas MK, Herbison GP (1990) Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336:1391–1396

    Article  PubMed  CAS  Google Scholar 

  38. Svedmyr N (1984) Is beta-adrenoceptor sensitivity a limiting factor in asthma therapy? In: Morley J (ed) Beta-adrenoceptors in asthma. Academic Press, London, pp 181–199

    Google Scholar 

  39. Tashkin DP, Conolly ME, Deutsch RI, Hui KK, Littner M, Scarpace P, Abrass I (1982) Subsensitization of beta-adrenoceptors in airway and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis 125:185

    PubMed  CAS  Google Scholar 

  40. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, Yates DM, Lucas MK, Li Q (1993) Regular inhaled β-agonist in asthma: effects on exacerbations and lung function. Thorax 48:134–138

    Article  PubMed  CAS  Google Scholar 

  41. Tokuyama K, Lötvall J, Löfdahl CG, Barnes PJ, Chung KF (1990) Inhaled formoterol inhibits both airflow obstruction and airway microvascular leakage in guinea pig. Eur J Pharmacol 3:155–160

    Google Scholar 

  42. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST (1990) Protection against allergeninduced asthma by salmeterol. Lancet 336:1338–1342

    Article  PubMed  CAS  Google Scholar 

  43. Ullman A, Svedmyr N (1988) Salmeterol, a new long-acting inhaled β2-adrenoceptor agonist: a comparison with salbutamol in asthmatic patients. Thorax 43:674–678

    Article  PubMed  CAS  Google Scholar 

  44. Ullman A, Hedner J, Svedmyr N (1990) Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. 142:571–575

    CAS  Google Scholar 

  45. Vathanen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield A (1988) Rebound increase in bronchial responsiveness after treatment withinhaled terbutaline. Lancet 1, 554–558

    Article  Google Scholar 

  46. Wallin A, Melander B, Rosenhall L, Sanström T, Wahlander L (1990) Formoterol, a new long acting β2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 45:259–261

    Article  PubMed  CAS  Google Scholar 

  47. Booth H, Fishwick K, Severeux G, Walter EH, Hendrick DJ (1993) Measurement of airways responsiveness in mid to moderate asthatics during and after 8 weeks of regularly inhaled salmeterol. Am Rev Respir Dis 147:4, A175

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Sahlgrenska University Hospital, S-413 45, Göteborg, Sweden

    Jan Lötvall & Nils Svedmyr

Authors
  1. Jan Lötvall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nils Svedmyr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lötvall, J., Svedmyr, N. Salmeterol: An inhaled /β2-agonist with prolonged duration of action. Lung 171, 249–264 (1993). https://doi.org/10.1007/BF03215869

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03215869

Key words

Search

Navigation